QNCX 1.98 Stock Price Quince Therapeutics, Inc.
Range: | 0.512-2.45 | Vol Avg: | 512215 | Last Div: | 0 | Changes: | -0.12 |
Beta: | 0.71 | Cap: | 0.09B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Thu May 09 2019 | Empoloyees: | 32 |
CUSIP: | 22053A107 | CIK: | 0001662774 | ISIN: | US22053A1079 | Country: | US |
CEO: | Dr. Dirk Thye M.D. | Website: | https://www.quincetx.com |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.